Tokyo Medical University Ibaraki Medical Center

Inashiki-gun 300-0395

2 studies enrolling now · 2 studies all time

What they study most

End Stage Kidney Disease, Primary IgA Nephropathy

Studies at this site

• Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) — Recruiting now
• A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression — Recruiting now